On Nov 16, 2023, the FDA approved another drug for those who have developed the PIK3CA. Mutation after first line treatment for the HR+HER- type. It’s another drug in the same vein as PIQRAY which also has to be used with Fulvestrant. This one is from AstraZeneca but it seems to have all the same side effects and problems that Piqray is known for. I got excited but it’s not a game changer I was hoping for.
still want to have a discussion with my ONC but it looks like Xeloda will still be my next best friend. I have included the link below if you fall into this category.
Still hoping for that miracle shot …
My radiation is progressing without any great changes…3 days left me fatigued but the thanksgiving break gave me some welcome respite. Back, hips and legs still achey and spasm prone…but hmm…do I feel a little better ? 🤞.
best wishes to you all! 🙏🙌